Carcinoma, Ovarian Epithelial: all 1,619 studies

Page 16 of 17. Open to participants first (245), then studies with results posted, then the rest; newest registration first within each.

• UCN-01 and Topotecan in Treating Patients With Recurrent, Persistent, or Progressive Advanced Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT00072267Phase 2
• Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and NeckCompletedNCT00063895Phase 1/2
• Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal CancerCompletedNCT00061308Phase 2
• Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive CancerCompletedNCT00060372Phase 1
• Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube CancerCompletedNCT00060359Phase 1
• PS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube CancerCompletedNCT00059618Phase 1
• CA125 and Ultrasound in Detecting Ovarian Cancer in Postmenopausal WomenCompletedNCT00058032Not applicable
• S0025 Irinotecan in Treating Patients With Refractory Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube CancerTerminatedNCT00053833Phase 2
• Research Study in Patients With Advanced Ovarian Epithelial CancerWithdrawnNCT00053235
• Carboplatin/Paclitaxel +/-Gemcitabine in Treating Patients With Ovarian Epithelial or Fallopian Tube CancerCompletedNCT00052468Phase 3
• A Study of Trabectedin in Patients With Advanced Ovarian CancerCompletedNCT00050414Phase 2
• Clinical Trial for Ovarian Cancer (OvaRex®)TerminatedNCT00050375Phase 3
• Gefitinib in Treating Patients With Cervical CancerCompletedNCT00049556Phase 2
• Study of OSI-211 vs. Topotecan in Patients With Relapsed Epithelial Ovarian CancerCompletedNCT00046800Phase 2
• S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian CancerCompletedNCT00043082Phase 3
• Imatinib Mesylate in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal CancerCompletedNCT00041041Phase 2
• Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential TumorCompletedNCT00039585Phase 2
• Clinical Trial to Screen Participants Who Are at High Genetic Risk for Ovarian CancerStatus unknownNCT00039559Not applicable
• Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung CancerTerminatedNCT00039091Phase 1
• Imatinib Mesylate in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal CancerCompletedNCT00036751Phase 2
• Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Ovarian CancerCompletedNCT00034151Phase 2
• Screening Women at High Genetic Risk for Ovarian CancerCompletedNCT00033488Not applicable
• 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)CompletedNCT00031681Phase 1
• Ixabepilone in Treating Patients With Relapsed and/or Refractory Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal CancerCompletedNCT00030706Phase 2
• Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney DysfunctionCompletedNCT00030498Phase 1
• Erlotinib and Carboplatin in Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT00030446Phase 2
• Bortezomib and Carboplatin in Treating Patients With Recurrent or Progressive Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT00028912Phase 1
• Combination Chemotherapy Regimens in Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube CancerCompletedNCT00028743Phase 3
• Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid TumorsCompletedNCT00028535Phase 1
• Fenretinide in Treating Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal CancerCompletedNCT00026091Phase 2
• S0114 Vaccine Therapy in Treating Patients With Gastric, Prostate, or Ovarian CancerTerminatedNCT00023634Phase 1
• TLK286 in Treating Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerCompletedNCT00022347Phase 2
• Squalamine Lactate Plus Carboplatin in Treating Patients With Recurrent or Refractory Stage III or Stage IV Ovarian CancerStatus unknownNCT00021385Phase 2
• Taurolidine in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerCompletedNCT00021034Phase 1
• Vaccine Therapy Plus Interleukin-2 in Treating Women With Stage IV, Recurrent, or Progressive Breast or Ovarian CancerCompletedNCT00019916Phase 1/2
• Irofulven in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal CancerCompletedNCT00019552Phase 2
• Carboxyamidotriazole in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT00019461Phase 2
• Gene Therapy and Biological Therapy in Treating Patients With Ovarian Epithelial CancerCompletedNCT00019136Phase 1
• Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal CancerStatus unknownNCT00017303Phase 2
• Fenretinide Followed by Surgery Compared With Surgery Alone in Preventing Ovarian Cancer in Patients at Increased RiskTerminatedNCT00017134Not applicable
• Interleukin-12 in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal CancerCompletedNCT00016289Phase 2
• Thalidomide in Treating Patients With Refractory or Resistant Epithelial Ovarian CancerCompletedNCT00016224Phase 2
• ZD9331 With or Without Topotecan in Treating Patients With Refractory or Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerCompletedNCT00014690Phase 2
• Lurtotecan Liposome in Treating Patients With Advanced or Recurrent Ovarian Epithelial CancerCompletedNCT00010179Phase 2
• Bryostatin 1 and Cisplatin in Treating Patients With Advanced Recurrent or Residual Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT00006942Phase 2
• Paclitaxel Plus Carboplatin With or Without Topotecan in Treating Patients With Stage IIB, Stage III, or Stage IV Ovarian Epithelial CancerCompletedNCT00006454Phase 3
• Oxaliplatin and Topotecan in Treating Patients With Previously Treated Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT00006391Phase 1
• Chemotherapy With or Without Surgery in Treating Patients With Recurrent Ovarian CancerTerminatedNCT00006356Phase 3
• Rebeccamycin Analogue in Treating Patients With Refractory Stage III or Stage IV Ovarian Epithelial CancerTerminatedNCT00006262Phase 2
• Nitrocamptothecin in Treating Patients With Advanced Ovarian CancerCompletedNCT00006230Phase 2
• SU5416 and Carboplatin to Treat Ovarian CancerCompletedNCT00006155Phase 1
• Gemcitabine Plus Cisplatin in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Is Recurrent or Has Not Responded to Platinum-based ChemotherapyCompletedNCT00006028Phase 2
• LMB-9 Immunotoxin in Treating Patients With Advanced Colon, Breast, Non-small Cell Lung, Bladder, Pancreatic, or Ovarian CancerCompletedNCT00005858Phase 1
• Oxaliplatin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Has Not Responded to Platinum- Based ChemotherapyCompletedNCT00005836Phase 2
• Treating Patients With Advanced Solid Tumors, Breast Cancer or Recurrent Ovarian CancerCompletedNCT00005807Phase 1
• ILX-295501 in Treating Patients With Stage III or Stage IV Ovarian Cancer That Has Not Responded to Previous TreatmentWithdrawnNCT00005645Phase 2
• Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial CancerTerminatedNCT00005612Phase 1/2
• Combination Chemotherapy in Treating Patients With Advanced Ovarian Epithelial CancerCompletedNCT00005051Phase 2
• Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal CancerCompletedNCT00005049Phase 2
• Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal CancerCompletedNCT00005046Phase 1
• Gene Therapy in Treating Women With Refractory or Relapsed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal CancerStatus unknownNCT00005025Phase 2
• Paclitaxel and Carboplatin With or Without Epirubicin in Treating Patients With Stage IIB, Stage III, or Stage IV Invasive Ovarian Epithelial, Fallopian Tube, or Peritoneal CancerCompletedNCT00004934Phase 3
• High-Dose Chemotherapy Compared With Standard Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer That Has Been Removed During SurgeryCompletedNCT00004921Phase 3
• Effect of Chemotherapy Given Either by Mouth or by Infusion on the Quality of Life of Patients With Recurrent Ovarian Epithelial CancerCompletedNCT00004909
• Carboplatin With or Without Thalidomide in Treating Patients With Ovarian Epithelial CancerCompletedNCT00004876Phase 2
• Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian CancerTerminatedNCT00004221Phase 2
• Oxaliplatin and Fluorouracil in Treating Patients With Recurrent Ovarian CancerStatus unknownNCT00004206Phase 2
• Radiolabeled Monoclonal Antibody Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory or Recurrent Ovarian Epithelial CancerCompletedNCT00004177Phase 1/2
• Amifostine in Treating Patients With Ovarian Epithelial Cancer Who Are Receiving ChemotherapyCompletedNCT00004166Phase 3
• Monoclonal Antibody Therapy in Treating Patients With Ovarian Cancer or Primary Peritoneal Cancer in Remission Following Surgery and ChemotherapyStatus unknownNCT00004115Phase 3
• Liposomal Cisplatin in Treating Patients With Recurrent Ovarian CancerCompletedNCT00004083Phase 2
• Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/NeuCompletedNCT00004074Phase 1
• Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal CancerStatus unknownNCT00004064Phase 2
• Docetaxel in Treating Patients With Recurrent or Refractory Ovarian or Primary Peritoneal CancerTerminatedNCT00004037Phase 2
• Tumor Vaccine and Interferon Gamma in Treating Patients With Refractory Epithelial Ovarian CancerCompletedNCT00004032Phase 1
• Bryostatin 1 in Treating Patients With Ovarian Epithelial CancerCompletedNCT00004008Phase 2
• Carboplatin Plus Paclitaxel or Docetaxel in Treating Patients With Ovarian Epithelial CancerCompletedNCT00003998Phase 3
• ISIS 5132 in Treating Patients With Metastatic or Recurrent Ovarian CancerCompletedNCT00003892Phase 2
• Toremifene in Treating Patients With Ovarian CancerWithdrawnNCT00003865Phase 2
• Quality-of-Life Study of Patients With Previously Treated Ovarian CancerTerminatedNCT00003794
• IM-862 in Treating Patients With Recurrent Ovarian CancerCompletedNCT00003773Phase 1
• Quality-of-Life Assessment in Patients With Ovarian CancerCompletedNCT00003772
• Radiolabeled Folic Acid and Imaging to Detect Ovarian CancerCompletedNCT00003763Not applicable
• Sequential Chemotherapy in Treating Patients With Residual Disease Following Surgery for Stage IIB, Stage III, or Stage IV Ovarian CancerStatus unknownNCT00003733Phase 2
• Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian CancerCompletedNCT00003732Phase 2
• Chemotherapy With or Without Surgery in Treating Patients With Stage II or Stage III Ovarian CancerCompletedNCT00003695Phase 3
• Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Metastatic Refractory Ovarian Cancer or Primary Peritoneal CancerCompletedNCT00003670Phase 2
• Gene Therapy in Treating Patients With Ovarian CancerCompletedNCT00003588Phase 1
• Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Ovarian CancerTerminatedNCT00003532Phase 2
• Aminocamptothecin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Cancer of the PeritoneumCompletedNCT00003523Phase 2
• Gene Therapy in Treating Patients With Advanced Recurrent or Persistent Ovarian Cancer or Primary Peritoneal CancerCompletedNCT00003450Phase 1
• Combination Chemotherapy in Treating Patients With Platinum-Resistant Recurrent Ovarian CancerCompletedNCT00003449Phase 2
• Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian Epithelial CancerCompletedNCT00003413Phase 2
• Vaccine Therapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial CancerTerminatedNCT00003386Phase 2
• Combination Chemotherapy Consisting of Gemcitabine And Topotecan in Treating Patients With Refractory or Recurrent Ovarian or Fallopian Tube CancerTerminatedNCT00003382Phase 1
• Cisplatin Plus Irinotecan in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal CancerCompletedNCT00003345Phase 2
• Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian CancerCompletedNCT00003322Phase 3
• Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian CancerCompletedNCT00003297Phase 1/2
• Chemosensitivity Testing to Assign Treatment for Patients With Stage III or Stage IV Ovarian CancerCompletedNCT00003214Phase 3
• Weekly Infusions of Paclitaxel in Treating Women With Stage III or Stage IV Ovarian Cancer Refractory to Paclitaxel and PlatinumStatus unknownNCT00003160Phase 2

← Carcinoma, Ovarian Epithelial overview